New York, June 10, 2026, 05:04 PM ET
- Parabilis Medicines finished its Nasdaq debut at $31.60, up 58% from the $20 IPO price. Shares opened at $33.35 and hit a session high of $34.02.
- Parabilis Medicines priced its upsized IPO, selling 33.5 million common shares to raise $670 million before fees. The company also expects a $75 million Regeneron private placement to go through with the offering.
- Parabilis shares rose on higher-than-expected demand for its Helicon drug platform. Investors are still looking to the main clinical trigger, a scheduled Phase 3 desmoid tumor trial in the first half of 2027.
Parabilis Medicines jumped in its Nasdaq debut Wednesday. Shares opened under PBLS and closed at $31.60, up 58% from the $20 IPO price. The company had priced a bigger-than-expected $670 million initial offering, topping the marketed range. Investors chased the deal harder than Parabilis suggested just a day before.
Parabilis moved quickly. Early Tuesday, the company was out marketing 33.3 million shares at $17 to $19 each, up from the initial 25 million share plan, Reuters reported. But by the evening, Parabilis priced 33.5 million shares at $20, above guidance. The stock is set to start trading Wednesday on the Nasdaq Global Select Market.
PBLS popped at the open, pricing at $33.35—above the offer. Shares moved between $26.61 and $34.02, with roughly 5.49 million traded, Benzinga data showed. The stock was last at $30.88 after hours, off 2.28% from the close but still up over 50% versus the IPO price.
Parabilis is pulling in more cash than the IPO proceeds on their own. The company expects $670 million in gross IPO proceeds before expenses. On top of that, Parabilis cut a deal to sell 4,166,666 shares at $18 a share to Regeneron Pharmaceuticals, or 90% of the IPO price, raising about $75 million in a concurrent private placement. The IPO is set to close around June 11, pending the usual conditions.
The stock got more eyes than a typical biotech IPO. BioPharma Dive reported Parabilis’s $670 million IPO was the biggest new stock sale yet for a venture-backed biotech, ahead of Moderna’s 2018 debut and Kailera Therapeutics’ deal from earlier this year. The publication counted 12 drug startups going public in 2026 so far, pulling in over $4.1 billion total.
Investors right now aren’t paying for revenue growth. They want to see a platform with room to run. Parabilis is still in the clinic. The biopharma focuses on Helicons, stabilized helical peptides designed to hit protein targets that other drugs miss. Parabilis is working on peptide drugs meant to get into cells and bind places where antibodies can’t go and small molecules often lose hold.
Regeneron’s role added more credibility to the debut. IPOX Research Associate Lukas Muehlbauer told Reuters the upsize sends a strong message that the biotech IPO pipeline looks much healthier than last year. He also called the Regeneron partnership outside validation for Parabilis’s technology.
Zolucatetide is Parabilis’s lead drug, part of the Helicon class targeting the Wnt/beta-catenin pathway. This cell-signaling track can push tumor growth if it gets too active. The company is going after desmoid tumors first—these are rare, show up in connective tissue. The drug is still in the trial phase and not yet approved.
Early results are part of the bull case, but data is still early. MedCity News, pulling from the IPO filing, said a Phase 1/2 trial of IV zolucatetide enrolled 38 people. Out of 25 patients with data through late February, all had tumor shrinkage. For 19 patients with at least two scans after baseline, 14 saw an objective response—tumor reduction at the bar set by the study. Parabilis plans to start a Phase 3 trial in desmoid tumors in the first half of 2027.
Parabilis is putting the cash toward more work on zolucatetide and its pipeline. About $150 million is earmarked for zolucatetide in desmoid tumors to reach topline Phase 3 results. The company plans to spend another $120 million on zolucatetide in other uses, with $190 million set aside for the rest of its pipeline through Phase 1. Parabilis said its current capital and Regeneron’s upfront payment should take it through the second half of 2029.
Chasing a big first-day pop here is risky. Parabilis is still clinical-stage, and early tumor-response numbers from small studies often don’t hold up in bigger, controlled trials. The desmoid tumor space already has competition: the FDA cleared Ogsiveo, or nirogacestat, in 2023 as the first approved option for adults with progressive desmoid tumors needing systemic therapy. MedCity has called it the only approved drug for this use. Phase 3 setbacks, new safety worries, or cooling biotech IPO appetite could all hit the stock fast and alter what investors paid at the open.
The next short-term step is procedural: seeing if the offering and Regeneron’s private placement actually close around June 11, and if underwriters pick up their 30-day option for another 5,025,000 shares. The bigger hurdle comes later, as Parabilis will need to turn the IPO buzz from Wednesday into real clinical progress when zolucatetide heads into a planned Phase 3 desmoid tumor trial in 2027.
